Mersana Therapeutics News

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Not Doing Enough For Some Investors As Its Shares Slump 25%

To the annoyance of some shareholders, Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares are down a considerable 25% in the last month, which continues a horrid run for the company. Instead of being

Simply Wall StJun 19 06:32 ET

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

GlobeNewswireMay 22 08:00 ET

Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)

TipRanksMay 14 10:05 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)

TipRanksMay 14 05:40 ET

Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis

Yahoo FinanceMay 10 15:15 ET

Truist Financial Sticks to Their Buy Rating for Mersana Therapeutics (MRSN)

TipRanksMay 10 08:09 ET

Earnings Call Summary | Mersana Therapeutics(MRSN.US) Q1 2024 Earnings Conference

The following is a summary of the Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript:Financial Performance:Mersana reported a healthy balance sheet for Q1 2024, with $183.1 million in

moomoo AIMay 9 18:31 ET · Conference Call

Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 9 14:09 ET

Mersana Therapeutics | 10-Q: Quarterly report

SEC announcementMay 9 09:02 ET · Announcements

Mersana Therapeutics Updates Corporate Presentation Online

TipRanksMay 9 07:22 ET

Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, Vs. Street Est of $8.5M

07:03 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M

MT NewswiresMay 9 07:03 ET

Mersana Therapeutics 1Q Research and Development Expenses $18.7M >MRSN

Mersana Therapeutics 1Q Research and Development Expenses $18.7M >MRSN

Dow JonesMay 9 07:01 ET

Express News | Mersana Therapeutics Inc - Continue to Expect Capital Resources Will Support Current Operating Plan Commitments Into 2026

ReutersMay 9 06:59 ET

Express News | Mersana Therapeutics Q1 Collaboration Revenue USD 9.245 Million

ReutersMay 9 06:59 ET

Express News | Mersana Therapeutics Q1 EPS USD -0.16

ReutersMay 9 06:59 ET

Express News | Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

ReutersMay 9 06:59 ET

Express News | Mersana Therapeutics Q1 Net Income USD -19.306 Million

ReutersMay 9 06:59 ET

Express News | Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersMay 3 16:30 ET

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

GlobeNewswireMay 2 08:00 ET

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Not Doing Enough For Some Investors As Its Shares Slump 34%

Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares have had a horrible month, losing 34% after a relatively good period beforehand.

Simply Wall StApr 26 06:32 ET